Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

CALGARY, Jan. 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) today announces its participation in the 9^th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. Mr. Donald J. McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.

Presentation Details:

Date: January 9^th

Time: 2:00pm PT

Duration: 30 minutes

Location: Room 3 (Ballroom Level) at the Hilton San Francisco Union Square

Mr. McCaffrey's presentation will be available on the Company website on the Media/Events page immediately prior to the scheduled presentation time.

To schedule a meeting with senior management in San Francisco during the event, please contact Investor Relations.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

For further information please visit www.resverlogix.com.

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog

For further information please contact:

Investor Relations

Email: ir@resverlogix.com

Phone: 403-254-9252

SOURCE Resverlogix Corp.